News & Updates

Show Multimedia Only

Once-daily roflumilast foam may bring relief in psoriasis

26 Jul 2025 by

Treatment with once-daily roflumilast foam appears to improve the signs and symptoms of psoriasis of the scalp and body, with low rates of adverse events, according to the results of the phase III ARRECTOR trial.

Once-daily roflumilast foam may bring relief in psoriasis

26 Jul 2025

Real-world use affirms RSVpreF efficacy at preventing LRTD in infants

26 Jul 2025

Maternal immunization with the bivalent respiratory syncytial virus (RSV) prefusion F vaccine (RSVpreF) helps lower the incidence of RSV-related lower respiratory tract disease (LRTD) and severe LRTD leading to hospitalization among infants from birth through age 6 months, according to real-world data from the BERNI study.

Real-world use affirms RSVpreF efficacy at preventing LRTD in infants

26 Jul 2025

$ABI-009 safe in children with refractory epilepsy$

ABI-009 safe in children with refractory epilepsy

25 Jul 2025

In the treatment of paediatric patients with medically and surgically refractory epilepsy, the use of ABI-009 appears safe and tolerable, with early signs of efficacy, according to data from a phase I study.

ABI-009 safe in children with refractory epilepsy

25 Jul 2025

BMI, CCI predict biologic response in psoriasis patients

25 Jul 2025

Several factors, including BMI and Charlson Comorbidity Index (CCI), can help predict treatment response among patients with psoriasis, suggests a study.

BMI, CCI predict biologic response in psoriasis patients

25 Jul 2025

Cenobamate cuts SUDEP risk

25 Jul 2025 by

A study presented at EAN 2025 demonstrates a reduction in the risk of sudden unexpected death in epilepsy (SUDEP) following treatment with the antiseizure medication (ASM) cenobamate among Spanish individuals in the phase III C021 study. The reductions were based on SUDEP-3 and SUDEP-7 risk scores.

Cenobamate cuts SUDEP risk

25 Jul 2025

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

25 Jul 2025

Treatment with nerandomilast helps preserve lung function in patients with idiopathic pulmonary fibrosis, as shown in the phase III FIBRONEER-IPF trial.

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

25 Jul 2025

Ivarmacitinib shows favourable risk–benefit profile in AD

24 Jul 2025

The selective oral Janus kinase 1 (JAK1) inhibitor ivarmacitinib helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adolescent and adult patients, while having a manageable safety profile, according to a phase III trial.

Ivarmacitinib shows favourable risk–benefit profile in AD

24 Jul 2025

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

24 Jul 2025

A recent phase III trial of NUC-1031/cisplatin has been terminated early due to ineffectiveness as first-line treatment for advanced biliary tract cancer (BTC).

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

24 Jul 2025

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

24 Jul 2025 by

Individuals with tardive dyskinesia (TD) report favourable outcomes with the VMAT2 inhibitor deutetrabenazine in an age subgroup analysis.

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

24 Jul 2025

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

24 Jul 2025

In the treatment of patients with relapsing polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper, the use of sarilumab appears to produce clinically important improvements in health-related quality of life and patient-reported outcomes, according to the results of a phase III study.

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

24 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Once-daily roflumilast foam may bring relief in psoriasis

Once-daily roflumilast foam may bring relief in psoriasis

Real-world use affirms RSVpreF efficacy at preventing LRTD in infants

Real-world use affirms RSVpreF efficacy at preventing LRTD in infants

ABI-009 safe in children with refractory epilepsy

ABI-009 safe in children with refractory epilepsy

BMI, CCI predict biologic response in psoriasis patients

BMI, CCI predict biologic response in psoriasis patients

Cenobamate cuts SUDEP risk

Cenobamate cuts SUDEP risk

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

Ivarmacitinib shows favourable risk–benefit profile in AD

Ivarmacitinib shows favourable risk–benefit profile in AD

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica